BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 30120496)

  • 21. Comparison of radiation and chemoradiation-induced sensorineural hearing loss in head and neck cancer patients.
    Mahdavi SR; Rezaeyan A; Nikoofar A; Bakhshandeh M; Farahani S; Cheraghi S
    J Cancer Res Ther; 2020; 16(3):539-545. PubMed ID: 32719264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
    Biró K
    Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hearing and tinnitus in head and neck cancer patients after chemoradiotherapy.
    Niemensivu R; Saarilahti K; Ylikoski J; Aarnisalo A; Mäkitie AA
    Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2509-14. PubMed ID: 26685859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hearing impairment after platinum-based chemotherapy in childhood.
    Einar-Jon E; Trausti O; Asgeir H; Christian M; Thomas W; Måns M; Jon K; Hannes P
    Pediatr Blood Cancer; 2011 Apr; 56(4):631-7. PubMed ID: 21298751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results of concurrent chemotherapy and hyperthermia in patients with recurrent cervical cancer after previous chemoradiation.
    Heijkoop ST; van Doorn HC; Stalpers LJ; Boere IA; van der Velden J; Franckena M; Westermann AM
    Int J Hyperthermia; 2014 Feb; 30(1):6-10. PubMed ID: 24156619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid shunting and hearing loss in patients treated for medulloblastoma.
    Guillaume DJ; Knight K; Marquez C; Kraemer DF; Bardo DM; Neuwelt EA
    J Neurosurg Pediatr; 2012 Apr; 9(4):421-7. PubMed ID: 22462709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma.
    Chen WC; Jackson A; Budnick AS; Pfister DG; Kraus DH; Hunt MA; Stambuk H; Levegrun S; Wolden SL
    Cancer; 2006 Feb; 106(4):820-9. PubMed ID: 16421885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.
    Bokemeyer C; Berger CC; Hartmann JT; Kollmannsberger C; Schmoll HJ; Kuczyk MA; Kanz L
    Br J Cancer; 1998 Apr; 77(8):1355-62. PubMed ID: 9579846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transient-evoked otoacoustic emissions in children after cisplatin chemotherapy.
    Allen GC; Tiu C; Koike K; Ritchey AK; Kurs-Lasky M; Wax MK
    Otolaryngol Head Neck Surg; 1998 May; 118(5):584-8. PubMed ID: 9591854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
    Hitchcock YJ; Tward JD; Szabo A; Bentz BG; Shrieve DC
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):779-88. PubMed ID: 18707819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Precision-scored parental report questions and HL-scaled tympanometry as informative measures of hearing in otitis media 1: Large-sample evidence on determinants and complementarity to pure-tone audiometry.
    Milovanovic J; Filipovic SA; Marchisio P; Haggard MP; Zhang MF; Spencer H;
    Int J Pediatr Otorhinolaryngol; 2016 Apr; 83():113-31. PubMed ID: 26968065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
    Freilich RJ; Kraus DH; Budnick AS; Bayer LA; Finlay JL
    Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ototoxicity from cisplatin therapy in childhood cancer.
    Coradini PP; Cigana L; Selistre SG; Rosito LS; Brunetto AL
    J Pediatr Hematol Oncol; 2007 Jun; 29(6):355-60. PubMed ID: 17551394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cisplatin-associated ototoxicity amongst cervical cancer patients: A prospective cohort study in south Africa.
    Paken J; Govender CD; Pillay M; Feyasa M; Sewram V
    PLoS One; 2023; 18(4):e0283639. PubMed ID: 37014872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer.
    Caballero M; Mackers P; Reig O; Buxo E; Navarrete P; Blanch JL; Grau JJ
    Oncology; 2017; 93(2):75-82. PubMed ID: 28511189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study.
    Haugnes HS; Stenklev NC; Brydøy M; Dahl O; Wilsgaard T; Laukli E; Fosså SD
    Acta Oncol; 2018 Aug; 57(8):1075-1083. PubMed ID: 29384420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of high-frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin-based chemotherapy.
    Abujamra AL; Escosteguy JR; Dall'Igna C; Manica D; Cigana LF; Coradini P; Brunetto A; Gregianin LJ
    Pediatr Blood Cancer; 2013 Mar; 60(3):474-8. PubMed ID: 22744939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Influence of hearing aids on monosyllabic test score and subjective everyday hearing].
    Thümmler R; Liebscher T; Hoppe U
    HNO; 2016 Aug; 64(8):595-600. PubMed ID: 27126291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Audiological profile of patients treated for childhood cancer.
    Liberman PH; Goffi-Gomez MV; Schultz C; Novaes PE; Lopes LF
    Braz J Otorhinolaryngol; 2016; 82(6):623-629. PubMed ID: 27156673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of Hearing Loss Prediction Tool for Cisplatin Chemotherapy and Radiation in Head and Neck Cancer Treatment.
    Deutsch BC; Collopy C; Kallogjeri D; Piccirillo JF
    JAMA Otolaryngol Head Neck Surg; 2021 Feb; 147(2):182-189. PubMed ID: 33300954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.